GRN and amyotrophic lateral sclerosis: As the translation of pre-clinical studies in mice to clinical trials is often unsuccessful [43], probably due to inter-species differences, our findings do show different regulatory mechanisms in the progranulin–sortilin axis and suggest that a therapeutic modulation of this pathway may lead to different outcomes in ALS/FTLD mouse models and in patients.